Cogent BiosciencesCOGT +1.36%25 14-Day RSI is 70.78 as of Jul. 06, 2026. GuruFocus rates COGT with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,419 Biotechnology companies, Cogent Biosciences ranks worse than 92.11% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Cogent Biosciences 14-Day RSI Related Terms
COGT vs SRRK, CGON, LGND: 14-Day RSI Comparison
For the Biotechnology subindustry, Cogent Biosciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences (COGT) has a 14-Day RSI of 70.78 as of Jul. 06, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Cogent Biosciences and its competitors. According to the industry distribution chart, Cogent Biosciences ranks #1307 out of 1419 companies in the Biotechnology industry, placing it in the top 92.1%.
Is Cogent Biosciences' 14-Day RSI too high?
Cogent Biosciences' current 14-Day RSI is 70.78. The Biotechnology industry median 14-Day RSI is 50.98. Cogent Biosciences' value of 70.78 is 38.8% above this industry median. Based on the distribution chart, Cogent Biosciences ranks #1307 out of 1419 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cogent Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' 14-Day RSI compare to SRRK and CGON?
According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #1307 out of 1419 companies for 14-Day RSI. This places Cogent Biosciences in the lower half of its industry. The industry median 14-Day RSI is 50.98. Cogent Biosciences' value of 70.78 is 38.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 50.98, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogent Biosciences's current 14-Day RSI of 70.78 is 38.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Cogent Biosciences and its competitors. For the Biotechnology industry, the median 14-Day RSI is 50.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogent Biosciences's current 14-Day RSI is 70.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current 14-Day RSI of 70.78. The current 14-Day RSI is 70.78 and 38.8% above the Biotechnology industry median of 50.98. Cogent Biosciences' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current 14-Day RSI is 70.78 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
25GF Score
Get the complete analysis for COGT
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGT has been successfully added to your 